Novel coronavirus pneumonia severe illness distinguishes and curative effect evaluation system
阅读说明：本技术 一种新型冠状病毒肺炎重症区分与疗效评价系统 (Novel coronavirus pneumonia severe illness distinguishes and curative effect evaluation system ) 是由 徐建华 滕祥云 石亚玲 张嘉琪 王大伟 黄若磐 胡薇 于 2020-10-22 设计创作，主要内容包括：本发明公开了一种新型冠状病毒肺炎重症区分与疗效评价系统。本发明提供了一种用于诊别新型冠状病毒肺炎重症与疗效评价的细胞因子标志物组合,选自如下细胞因子中的一种或几种组合：包括：Eotaxin-2、IP-10、IL-18Rb、IL-18、OPN、IL-2Rb、GDF-15、IL-12p40。并基于此提供了一种新型冠状病毒肺炎重症区分与疗效评价系统,包括预设值模块、数据收集模块、数据存储模块、数据处理模块、结果显示模块。所述系统在区分新型冠状病毒肺炎重症与非重症方面具有很好的应用价值,同时还可应用于重症患者的疗效评价,对于新型冠状病毒肺炎的防控具有重要的应用价值和意义。(The invention discloses a novel coronavirus pneumonia severe distinguishing and curative effect evaluating system. The invention provides a cytokine marker combination for diagnosing severe and curative effect evaluation of novel coronavirus pneumonia, which is selected from one or more of the following cytokines: the method comprises the following steps: eotaxin-2, IP-10, IL-18Rb, IL-18, OPN, IL-2Rb, GDF-15, IL-12p 40. Based on the data, the system for distinguishing severe coronavirus pneumonia and evaluating curative effect of severe coronavirus pneumonia comprises a preset value module, a data collection module, a data storage module, a data processing module and a result display module. The system has good application value in distinguishing severe and non-severe cases of the novel coronavirus pneumonia, can be applied to the curative effect evaluation of severe patients, and has important application value and significance in prevention and control of the novel coronavirus pneumonia.)
1. A cell factor marker combination for severe diagnosis and/or curative effect evaluation of novel coronavirus pneumonia, which is characterized by comprising one or more of the following cell factors: the method comprises the following steps: eotaxin-2, IP-10, IL-18Rb, IL-18, OPN, IL-2Rb, GDF-15, IL-12p 40.
2. A cytokine marker combination for severe screening and/or efficacy assessment of novel coronavirus pneumonia, wherein the severe screening is used for distinguishing severe screening from non-severe screening, wherein the non-severe screening comprises healthy, asymptomatic, mild, normal and convalescent screening;
(1) the cytokine marker combination for distinguishing severe and healthy state of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
(2) the cytokine marker combination for distinguishing severe and asymptomatic pneumonia of the novel coronavirus and evaluating the curative effect is selected from one or more of the following cytokines:
(3) the cytokine marker combination for distinguishing severe and mild type of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
(4) the cytokine marker combination for distinguishing severe cases from common types of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
(5) the cytokine marker combination for distinguishing severe cases and rehabilitation of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
。
3. use of the cytokine marker combination of claim 1 or 2 as a marker for severe cases of novel coronavirus pneumonia or for evaluating the efficacy of such cases.
4. Use of a cytokine marker combination according to claim 1 or 2 for the preparation of a product for the severe case discrimination or efficacy assessment of novel coronavirus pneumonia.
5. Use of the detection reagent of the cytokine marker combination according to claim 1 or 2 for the preparation of a product for severe cases of novel coronavirus pneumonia or for the evaluation of therapeutic effect.
6. A novel coronavirus pneumonia severe distinguishing and curative effect evaluating system is characterized by comprising a preset value module, a data collecting module, a data storage module, a data processing module and a result display module;
(1) the pre-set value module comprises the concentration values of the cytokine markers in claim 1 corresponding to severe versus non-severe cases:
(2) The data collection module comprises a data monitoring module and/or a data entry module, and is used for collecting and/or entering the concentration value of the cytokine marker in the claim 1;
(3) the data storage module is used for storing the information of the data collection module;
(4) the data processing module is used for comparing the information of the preset value module and the data collecting module;
(5) and the data display module is used for displaying the result of the data processing module.
7. The system of claim 6, wherein the result of step (5) is displayed according to:
the concentration values of the cytokine markers are determined according to the following criteria for severe and non-severe cases:
8. the system of claim 6, further comprising a communication device association apparatus or interface for connecting to a computer, a mobile phone, a cloud storage device, or other mobile devices;
the data collection module is connected with noninvasive medical detection equipment, and the noninvasive medical detection equipment comprises a cytokine concentration tester.
9. Use of the system according to any one of claims 6 to 8 for the preparation of a novel reagent kit for the treatment and evaluation of severe cases of coronavirus pneumonia.
10. A kit for staging and/or efficacy assessment of a novel coronavirus pneumonia, comprising reagents for detecting the level of a cytokine marker according to claim 1, or comprising a system according to any one of claims 6 to 8.
Technical Field
The invention belongs to the technical field of biological medicines. More particularly, the invention relates to a novel coronavirus pneumonia severe distinguishing and curative effect evaluating system.
Background
The novel coronavirus pneumonia caused by the novel coronavirus (SARS-CoV-2) is mainly manifested by fever, dry cough, debilitation, etc., and a few patients are accompanied with upper respiratory tract and digestive tract symptoms such as nasal obstruction, watery nasal discharge, diarrhea, etc.; severe cases often develop dyspnea after 1 week, and severe cases rapidly progress to acute respiratory distress syndrome, septic shock, uncorrectable metabolic acidosis and hemorrhagic coagulation dysfunction, multiple organ failure, and the like. Therefore, it is important to distinguish between severe cases in response to determining a treatment regimen.
At present, the determination of the severe COVID-19 mainly depends on the evaluation of vital signs, SpO2, consciousness state and clinical routine organ functions, but is not favorable for clinically and rapidly guiding related treatment due to a plurality of factors such as large heterogeneity of clinical manifestations of patients, limitation of result judgment and the like. The finding of a rapid and stable novel coronavirus pneumonia severe distinguishing and curative effect evaluation system has important clinical application value.
Disclosure of Invention
The invention aims to provide a cytokine marker combination for diagnosing severe and curative effect evaluation of novel coronavirus pneumonia.
Another objective of the invention is to provide a novel coronavirus pneumonia severe illness and curative effect evaluation system.
The invention further aims to provide application of the marker combination and the marker system in preparation of a novel coronavirus pneumonia severe region and curative effect evaluation kit.
The above purpose of the invention is realized by the following technical scheme:
the invention is obtained by a great amount of research and research, and various cytokines can be well used for diagnosing and distinguishing the severe cases of the novel coronavirus pneumonia from other non-severe cases including rehabilitation groups, so the invention has high application value in the aspects of the severe cases and the curative effect evaluation of the novel coronavirus pneumonia.
The invention therefore claims:
a cell factor marker combination for diagnosing severe and curative effect evaluation of novel coronavirus pneumonia is selected from one or more of the following cell factors: the method comprises the following steps: eotaxin-2, IP-10, IL-18Rb, IL-18, OPN, IL-2Rb, GDF-15, IL-12p 40.
Also provided are cytokine marker combinations that distinguish severe cases of novel coronavirus pneumonia from a range of non-severe cases, including healthy, asymptomatic, mild, normal, convalescent, and specifically including the following:
(1) the cytokine marker combination for distinguishing severe and healthy state of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
IP-10
TFPI
MPIF-1
WIF-1
bIG-H3
IL-8
Cystatin B
RBP4
GDF-15
IGF-2R
IL-18
IL-1RI
TGFb2
IL-10
EGF
E-Cadherin
IGFBP-4
CD200
IL-17C
Fas
TGFb1
Endoglin
GDNF
Midkine
VCAM-1
HVEM
IL-1F7
IL-1F9
FGF-4
Pref-1
uPAR
IL-20
sFRP-3
I-TAC
L-Selectin
NAP-2
Layilin
CHI3L1
OPG
Fetuin A
IGFBP-3
PDGF-AA
TRAIL R1
Epo R
TLR2
TGFb3
Transferrin
IL-32alpha
GRO
MMP-1
TIM-3
XEDAR
HCC-1
IL-18Rb
MCP-2
SCF
OPN
FGF-7
ADAM8
CD14
FABP2
Nidogen-1
DR3
Cystatin E M
Galectin-9
B2M
Leptin
TREM-1
CD58
IGF-2
RAGE
ANGPTL4
HGF
IL-1R5
IL-5Ra
Chemerin
ESAM
IL-1F8
TRAIL R3
IL-24
IGFBP-2
IL-23
CD99
IL-12p40
FGF-21
LIGHT
ALCAM
Testican 2
MIF
MIP-3b
MCP-4
ErbB3
Cystatin A
b-NGF
CEACAM-1
MIP-3a
IGFBP-1
CD40
NT-3
IL-29
CXCL16
Syndecan-1
BDNF
CTACK
IGFBP-6
IL-17B
Pentraxin 3
LIF
IL-2Rb
CEA
6Ckine
GCP-2
IGF-1
Cathepsin L
TECK
PECAM-1
BLC
GH
Eotaxin-2
MCSF R
EGF R
MSP
Axl
Shh-N
Trappin-2
MCP-1
MMP-13
HGF R
NSE
RANTES
B7-H3
ST2
Activin A
IL-1R6
HB-EGF
Renin
IL-18BPa
CCL28
NGF R
VEGF-D
TIMP-4
Fractalkine
ADAM12
SLAM
Lipocalin-2
HCC-4
FGF-9
IL-2Ra
VEGF R2
aFGF
Desmoglein 2
Decorin
DcR3
EG-VEGF
Tie-2
(2) the cytokine marker combination for distinguishing severe and asymptomatic pneumonia of the novel coronavirus and evaluating the curative effect is selected from one or more of the following cytokines:
(3) the cytokine marker combination for distinguishing severe and mild type of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
FLRG
IL-5
IL-10Rb
IL-3
FGF-19
FAP
IL-18Rb
TNF RII
IP-10
Contactin-2
IL-18
IL-12p40
GDF-15
bIG-H3
NAP-2
IL-7
TGFb1
CD40
PDGF-AA
TRAIL R2
NSE
DAN
OPN
IGFBP-6
LAG-3
TIM-3
CEA
Troponin I
IL-24
Thrombospondin-5
HGF
ADAM8
VEGF R2
Dkk-4
G-CSF R
Activin A
RANK
SDF-1a
IL-1b
CXCL16
IGFBP-3
Eotaxin-2
IL-2Rb
E-Cadherin
IL-17B R
Siglec-5
IL-4
MIG
RBP4
NCAM-1
IL-27
Kallikrein 14
FAS L
IL-17
HCC-4
TSP-1
Adiponectin
SDF-1b
BAFF
WIF-1
Nidogen-1
DKK-1
IFNg
BMP-2
SCF R
MMP-10
Furin
SOST
Shh-N
Fractalkine
TNF RI
BMP-9
IL-2Rg
TRAIL R1
IL-13R2
Cadherin-13
aFGF
TGFb2
Fetuin A
CD200
OPG
TACI
FOLR1
IFNab R2
MIF
I-TAC
IL-18BPa
GITR
IL-15
GRO
TIMP-4
SCF
Resistin
IL-1a
IL-23
ANGPTL3
APRIL
IGF-2
IGF-1R
GASP-2
hCGb
uPA
IL-13
IL-16
DcR3
FABP2
HAI-2
(4) the cytokine marker combination for distinguishing severe cases from common types of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
(5) the cytokine marker combination for distinguishing severe cases and rehabilitation of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
Eotaxin-2
Notch-1
EDA-A2
Prostasin
FGF-19
RBP4
MCP-2
MSP
IP-10
CTLA4
IL-1a
CD48
B7-H1
Tie-1
HB-EGF
PF4
OPN
FGF-4
IL-1F10
HCC-1
GDF-15
Cystatin A
MCP-4
bFGF
GRO
MCP-1
bIG-H3
Angiostatin
ANGPTL3
IGF-1
Decorin
EGF R
ENA-78
TIM-3
CD58
IL-13R2
NOV
Ck beta 8-1
LRIG3
NGF R
IL-17E
DNAM-1
MIF
IL-18Rb
MMP-8
ErbB4
HGF R
IL-7
Eotaxin
PSA-free
Kallikrein 14
Osteoactivin
FAP
IGFBP-2
IFNg
C5a
IL-12p40
Thrombomodulin
ADAM8
Fetuin A
AFP
IL-23
Mer
ErbB3
Fractalkine
Nectin-4
ADAM12
IL-1F5
MDC
Shh-N
S100A8
Insulin
IL-18
MIP-1a
CEACAM-1
Syndecan-4
HGF
IL-21
IL-2Rb
TNFb
LOX-1
IL-6R
Cathepsin B
BTC
OPG
ACE-2
TARC
Syndecan-1
more importantly, based on the above results, the invention provides a novel coronavirus pneumonia severe illness and curative effect evaluation system, which comprises a preset value module, a data collection module, a data storage module, a data processing module and a result display module;
(1) the preset value module comprises concentration values of the cytokine markers corresponding to severe cases and non-severe cases:
(2) the data collection module comprises a data monitoring module and/or a data entry module and is used for collecting and/or entering the concentration value of the cytokine marker;
(3) the data storage module is used for storing the information of the data collection module;
(4) the data processing module is used for comparing the information of the preset value module and the data collecting module;
(5) and the data display module is used for displaying the result of the data processing module.
The result display basis of the step (5) is as follows:
the concentration values of the cytokine markers are determined according to the following criteria for severe and non-severe cases:
furthermore, the system can also comprise a communication equipment association device or an interface, wherein the communication equipment association device or the interface is used for connecting a computer, a mobile phone, a storage cloud end or other mobile equipment;
the data collection module can also be connected with a noninvasive medical detection device, and the noninvasive medical detection device comprises a cytokine concentration tester.
In addition, the application of the above cytokine marker combination as a novel marker for severe cases of coronavirus pneumonia or for efficacy evaluation, the application in the preparation of products for severe cases of coronavirus pneumonia or for efficacy evaluation, and the application of a detection reagent of the cytokine marker combination in the preparation of products for severe cases of coronavirus pneumonia or for efficacy evaluation are all within the protection scope of the present invention.
Meanwhile, the application of the system in preparing a novel coronavirus pneumonia severe distinguishing and curative effect evaluation kit also belongs to the protection scope of the invention.
In addition, it should be noted that, in the research results of the present invention, it is clear that: a cytokine marker combination that distinguishes between severe and healthy, severe and asymptomatic, severe and mild, severe and general, severe and convalescent; the differential factors can be further analyzed to obtain a distinguishing system for distinguishing severe cases from healthy cases, distinguishing severe cases from asymptomatic cases, distinguishing severe cases from mild cases, distinguishing severe cases from general cases, and distinguishing severe cases from recovery cases. Has positive significance for the triage treatment of patients with the novel coronavirus pneumonia.
The invention has the following beneficial effects:
the invention provides a cytokine marker combination for distinguishing severe and non-severe cases of novel coronavirus pneumonia and evaluating curative effect, and simultaneously provides a system for distinguishing severe and non-severe cases of novel coronavirus pneumonia and evaluating curative effect based on the cytokine marker combination.
Drawings
FIG. 1 is a Wien diagram of differential protein production between the heavy and other groups, where the number "8" represents: the number of overlapping difference factors obtained by comparing the heavy type group with the healthy group, the asymptomatic group, the light type group and the normal type group is 8, namely the 8 difference factors exist in the difference factors obtained by comparing the heavy type group with the healthy group, the asymptomatic group, the light type group and the normal type group.
FIG. 2 is a trend graph of the expression levels of 8 overlapping proteins, showing the expression of cytokines at different severity of the disease.
FIG. 3 is a graph showing that the differential factors are mainly enriched in the pathways of 'interaction of cytokine and receptor thereof', 'Toll-like receptor signaling pathway', 'interaction of viral protein and cytokine and receptor thereof', etc. by performing GO and KEGG analysis on protein functions by using the R software package 'clusterProfiler'.
FIG. 4 shows that GO analysis shows that the differential factors are mainly involved in biological processes such as "T cell and NK mediated immune response".
FIG. 5 shows that the differential factors function to regulate "cytokine and its receptor activity and binding".
FIG. 6 is a graph of the construction of a ROC curve using the R software package "pROC" and the calculation of the area under the ROC curve (AUC); for patients with heavy and non-heavy type, GDF-15(AUC 0.887), IP-10(AUC 0.858), OPN (AUC 0.858), Eotaxin-2(AUC 0.798), IL-18(AUC 0.792), IL-12p40(AUC 0.728) have better diagnostic efficacy.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
Example 1
1. Data and Experimental methods
1.1 study object
This study retrospectively analyzed 131 patients with Sars-cov-2 infection from 1 month to 5 months of 2020, 14 asymptomatic patients according to the national health and wellness committee "protocol for prevention and treatment of new coronary pneumonia" (6 th edition), 12 light patients, 34 general patients, and 18 severe/critical patients according to the new guidelines for diagnosis and treatment of coronavirus, and 33 convalescent patients according to the standard for discharge from convalescence prescribed by the guidelines. 20 healthy control samples were from the university of medicine, cis-de hospital, guangzhou. Samples are collected in early stage of diseases, and the collection time of the samples of patients in the rehabilitation group is from three days before discharge to 20 days after discharge.
1.2 antibody array Q440
COVID19 Cytokines adopts Riboao QAH-CAA-440 protein chip to measure the level of biomarkers in 131 serum samples, and the levels of COVID19 serum Cytokines of different typing patients in the samples are analyzed and observed.
Specifically, protein screening was performed using a cytokine array Q440(QAH-CAA-440, RayBiotech, Inc, Peachtree Corners, GA, USA) that can quantitatively detect 440 kinds of human serum proteins. Antibody array manipulations were performed exactly according to the manufacturer's instructions. Briefly, the array was dried at room temperature for 2 hours, then plugged by adding 100 μ l of 2-fold diluted sample diluent to each well, and after 30 minutes the sample diluent was aspirated. Mu.l of 2-fold diluted serum samples were added to each well and incubated overnight at 4 ℃. The slides were washed 5 times for 5min with wash buffer I and then 3 times for 5min with wash buffer II. Wash buffer was blotted dry and 80ul biotin-conjugated antibody mix was added to each well and incubated for 2 hours at room temperature. After washing the array, 80ul of AlexaFluor 555-conjugated streptavidin was added to each well and incubated for 1 hour at room temperature in the absence of light. Finally, the signal was scanned and extracted using an InnoScan310 scanner (Innopsys, carbone, france).
1.3 statistical analysis
And determining the influence of the controllable factors on the research result by analyzing the contribution of the variation from different sources to the total variation in the research. Differentially Expressed Proteins (DEP) are defined as p-values (p. val) less than 0.05 and foldchange greater than 1.2 or less than 0.83(absolutelogFC > 0.263). All statistics were analyzed using R software (version 3.6.3).
Principal component analysis and hierarchical clustering analysis are based on differences in protein expression patterns to analyze differences between different sets of samples and proteins. GO analysis and KEGG enrichment analysis determined significant enrichment of protein function and signaling pathways with p values < 0.05. PCA (R package "ggbilot"), hierarchical cluster analysis (R package "gplots"), KEGG enrichment analysis (R package "clusterProfiler"), and GO enrichment analysis (R package "org.hs.e.db" and "clusterProfiler") were analyzed using R software (version 3.6.3). An ROC curve is constructed by using an R software package 'pROC', and the diagnostic value of the protein to different stages and different symptoms of COVID-19 is evaluated.
2. Results of the experiment
The statistical data are shown in Table 1
TABLE 1
2.1 pairwise differential comparisons between groups, Differentially Expressed Proteins (DEPs) were defined as p-value (P.Val) less than 0.05, foldchange greater than 1.2, or less than 0.83(absolutelogFC > 0.263). 160 proteins which are different between a healthy control group and a heavy group are screened out in the experiment; 56 differential proteins between the asymptomatic group and the heavy group; there were 107 differential proteins between the light and heavy groups; there were 60 differential proteins between the normal and heavy groups; there were 88 different proteins between the convalescent group and the heavy group.
Making a Wein diagram of the differential proteins of the screened heavy type group, the screened asymptomatic group, the screened light type group and the screened common type group respectively to obtain 8 overlapped cytokines, wherein the overlapping cytokines comprise: eotaxin-2, IP-10, IL-18Rb, IL-18, OPN, IL-2Rb, GDF-15, IL-12p 40. See fig. 1.
Simultaneously, 71 cytokines unique to healthy control groups and heavy groups, 15 cytokines unique to asymptomatic groups and heavy groups, 41 cytokines unique to light groups and heavy groups, 8 cytokines unique to common groups and heavy groups and 28 cytokines unique to convalescent groups and heavy groups are obtained.
2.2A trend graph was made using the expression levels of 8 proteins overlaid to observe cytokine expression at different severity of disease, see FIG. 2.
2.3 GO and KEGG analysis of protein function with R software package "clusterProfiler". KEGG analysis shows that the differential factors are mainly enriched in pathways such as 'interaction of cytokines and receptors thereof', 'Toll-like receptor signal pathway', 'interaction of viral proteins and cytokines and receptors thereof', and the like, which are shown in figure 3. GO analysis shows that the differential factors are mainly involved in biological processes such as 'T cell and NK mediated immune response' (figure 4), and play a role in regulating 'activity and binding of cytokines and receptors thereof' (figure 5). The cytokine function is shown in table 2.
TABLE 2
2.4 Using the R software package "pROC", we constructed ROC curves and calculated the area under the ROC curve (AUC). For both the patients with severe and non-severe symptoms, GDF-15(AUC 0.887), IP-10(AUC 0.858), OPN (AUC 0.858), Eotaxin-2(AUC 0.798), IL-18(AUC 0.792), IL-12p40(AUC 0.728) had better diagnostic efficacy, as shown in fig. 6.
Example 2
Based on the above results, the present invention provides a cytokine marker combination for diagnosing severe and curative effect evaluation of novel coronavirus pneumonia, which is selected from one or more of the following cytokines: the method comprises the following steps: eotaxin-2, IP-10, IL-18Rb, IL-18, OPN, IL-2Rb, GDF-15, IL-12p 40.
Also provided are a series of cytokine marker combinations for distinguishing severe cases and non-severe cases of the novel coronavirus pneumonia and evaluating curative effect, wherein the non-severe cases comprise health, no symptoms, light types, common types and rehabilitation, and specifically comprise the following steps:
(1) the cytokine marker combination for distinguishing severe and healthy state of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
(2) the cytokine marker combination for distinguishing severe and asymptomatic pneumonia of the novel coronavirus and evaluating the curative effect is selected from one or more of the following cytokines:
OPN
Clusterin
LDL R
MICA
Renin
IL-29
IL-18Rb
IL-2
IL-18
Decorin
CD163
IL-17B
GRO
MPIF-1
Legumain
IL-24
IP-10
TRAIL R2
TFPI
IL-23
IL-18BPa
IL-15
FLRG
Fetuin A
Eotaxin-2
MIP-3a
DLL1
hCGb
MIF
Leptin R
TNFb
Eotaxin
Syndecan-1
EDA-A2
L1CAM-2
ANG-4
MCP-2
IGFBP-6
MIP-1a
IL-2Rb
6Ckine
IL-12p40
IFNg
RBP4
Cystatin C
CD84
NSE
Galectin-3
GDF-15
IL-21
Pepsinogen I
Mer
MMP-8
CD23
CTACK
EMMPRIN
(3) the cytokine marker combination for distinguishing severe and mild type of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
(4) the cytokine marker combination for distinguishing severe cases from common types of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
hCGb
CEACAM-1
ADAM8
Nidogen-1
bIG-H3
SIGIRR
Eotaxin-2
FGF-9
IL-18Rb
Cathepsin B
TACE
Prolactin
Cystatin E M
B7-H1
IL-18BPa
HB-EGF
IL-18
IGFBP-3
Kallikrein 14
IFNab R2
OPG
Cystatin A
IGFBP-1
IL-1F10
IGF-1R
Cadherin-4
CEACAM-5
MBL
Fractalkine
SDF-1a
GDF-15
L-Selectin
HGF
GH
OPN
ANGPTL3
IL-21
IGFBP-2
ESAM
Layilin
FGF-19
CA15-3
IL-1RII
CD23
IL-3
IGFBP-4
FGF-7
IL-1R6
B7-H3
Insulin
IL-2Rb
CHI3L1
AFP
NGF R
IP-10
Eotaxin
IL-12p40
FAP
Syndecan-1
IL-1F5
(5) the cytokine marker combination for distinguishing severe cases and rehabilitation of the novel coronavirus pneumonia and evaluating the curative effect is selected from one or more of the following cytokines:
more importantly, based on the above results, the invention provides a novel coronavirus pneumonia severe illness and curative effect evaluation system, which comprises a preset value module, a data collection module, a data storage module, a data processing module and a result display module;
(1) the preset value module comprises concentration values of the cytokine markers corresponding to severe cases and non-severe cases:
cytokine (pg/ml)
Severe illness
Non-severe disease
IP-10
1657.431
858.5427
OPN
44767.89
20083.95
IL-2Rb
505.336
1955.144
IL-18Rb
46.04179
727.1648
IL-18
8821.305
2679.998
GDF-15
589.8844
167.732
Eotaxin-2
62.98553
126.6738
IL-12p40
36.44589
118.7969
(2) The data collection module comprises a data monitoring module and/or a data entry module and is used for collecting and/or entering the concentration value of the cytokine marker;
(3) the data storage module is used for storing the information of the data collection module;
(4) the data processing module is used for comparing the information of the preset value module and the data collecting module;
(5) and the data display module is used for displaying the result of the data processing module.
The result display basis of the step (5) is as follows:
the concentration values of the cytokine markers are determined according to the following criteria for severe and non-severe cases:
furthermore, the system can also comprise a communication equipment association device or an interface, wherein the communication equipment association device or the interface is used for connecting a computer, a mobile phone, a storage cloud end or other mobile equipment;
the data collection module can also be connected with a noninvasive medical detection device, and the noninvasive medical detection device comprises a cytokine concentration tester.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.